| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pfizer, Inc.$24.17
-0.02 (-0.09%)
A 92Pipeline Score Fair Value Pharma · Commercial
Market Cap
147.62 B
EPS
1.31
P/E Ratio
19.86 $
Value Trade
785.95 M
SEC Financials
Q1 2026Dilution Risk
Revenue
14.45 B
R&D Expenses
2.49 B
Operating CF
2.62 B
Total Assets
207.62 B
Total Liabilities
117.21 B
Equity
90.10 B
D/E Ratio
12,345
0.58 %
Week
-5.3 %
1 Month
-3.03 %
3 Month
5.35 %
6 Month
-35.59 %
5 Year
5,929.79 %
All Time
Cash Data
Cash Position
9.89 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
27.52 M
52 Week Range
23.06 - 28.75
% held by Insiders
0.11 %
% held by Institutions
69.91 %
Enterprise Value
199.30 B
Total Shares
5.70 B
Short %
3.38 %
Float Shares
4.84 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pfizer, Inc.
324Total events
20Upcoming
150Tier-1 (high impact)
2014 – 2031Coverage
Upcoming catalysts 20
Dec 2027
T2Restructuring Layoffs
First phase of manufacturing optimization program expected to save ~$1.5B by end of 2027
TBD
T1NDA Submission
Pfizer plans to submit regulatory filings for PF-07307405 (LB6V) based on Phase 3 VALOR results
TBD
T1Full Results
Detailed results from MagnetisMM-5 to be submitted for presentation at future medical congress
TBD
T1FDA Filing Accepted
Regulatory filings planned with global health authorities for PADCEV + Keytruda in cisplatin-eligible MIBC
TBD
T1FDA Filing Accepted
Detailed results to be shared with FDA to support potential approval for BRAFTOVI + cetuximab + FOLFIRI
TBD
T2Oral Presentation
Detailed results from Cohort 3 to be submitted for presentation at upcoming medical meeting
Event history 304
Jun 24, 2026
▲FDA ApprovalPalbociclibApprovedFDA Decision
FDA approves IBRANCE regimen for HR+, HER2+ metastatic breast cancer frontline maintenance
HR+, HER2+ metastatic breast cancer frontline maintenancesource ↗
Jun 23, 2026
●PublicationPresentation
Landmark publication demonstrating clinical PK predictions using multi-tissue chip platform
Jun 22, 2026
◆Topline Readoutsigvotatug vedotinClinical Data
Topline Phase 3 results for Sigvotatug Vedotin
previously treated metastatic non-squamous non-small cell lung cancersource ↗
Jun 8, 2026
▲Label ExpansionHYMPAVZIApprovedFDA Decision
FDA approves expanded indication for HYMPAVZI to include hemophilia A or B patients with inhibitors and pediatric patients
hemophilia A or B with inhibitors (12+ years) and pediatric (6-11 years) with or without inhibitorssource ↗
Jun 6, 2026
▲Topline ReadoutBerobenatideClinical Data
Phase 2b topline results for Berobenatide in obesity
obesitysource ↗
Jun 6, 2026
◆Oral PresentationPF'3944Presentation
Detailed results from VESPER-3 to be presented at ADA 86th Scientific Sessions
obesity or overweight without type 2 diabetessource ↗
Jun 2, 2026
◆Oral PresentationTUKYSAPresentation
Efficacy and safety of tucatinib plus trastuzumab and pertuzumab as maintenance therapy by subgroups
HER2+ metastatic breast cancersource ↗
Jun 1, 2026
▲Oral PresentationTALZENNAPresentation
Late-breaking oral presentation of TALAPRO-3 results at ASCO 2026
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
Jun 1, 2026
▲Primary Endpoint MetTALZENNAClinical Data
TALAPRO-3 met primary endpoint of rPFS
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
Jun 1, 2026
▲Full ResultsTALZENNAClinical Data
Simultaneous publication of TALAPRO-3 results in New England Journal of Medicine
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
Drug Pipeline Intelligence
A92
Pipeline Score $124.9B
Pipeline ValueFair Value
Valuation Signal758
Drugs Scored2.8x
rNPV / MCap Top 99%
Large Pharma (rank 10 of 911)
Percentile RankPfizer, Inc. earns an A-grade pipeline score (92/100), with $124.9B risk-adjusted pipeline value, led by Epogen in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epogen Monoclonal antibody | Chronic Kidney Disease | Phase 3 | NCT01473407 | 57% | $14.1B | COMPLETED | 612 | - | - | Feb 11, 2014 | - | Sep 10, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TALZENNA | metastatic prostate cancer | Phase 3 | 2026-06-01 | risk reduction: 52%; hazard ratio: 0.48; confidence interval: 0.36–0.65; p value: < 0.0001; r PFS three years treatment: 77%; r PFS three years placebo: 56%; median r PFS placebo: 46 months; r PFS BRA: treatment 77%, placebo 49%, hazard ratio 0.37, confidence interval 0.22–0.61; r PFS non BRA: treatment 76%, placebo 60%, hazard ratio 0.57, confidence interval 0.39–0.82; OS hazard ratio: 0.77; OS confidence interval: 0.56–1.04; OS p value: 0.09; time to PSA progression hazard ratio: 0.51; time to PSA progression confidence interval: 0.37–0.71; time to PSA progression p value: < 0.0001; time to subsequent therapy hazard ratio: 0.51; time to subsequent therapy confidence interval: 0.38–0.70; time to subsequent therapy p value: < 0.0001 Read More | TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Read More | |
TALZENNA | metastatic prostate cancer | Phase 3 | 2026-06-01 | risk reduction: 52%; hazard ratio: 0.48; confidence interval: 0.36–0.65; p value: < 0.0001; r PFS three years treatment: 77%; r PFS three years placebo: 56%; median r PFS placebo: 46 months; r PFS BRA: treatment 77%, placebo 49%, hazard ratio 0.37, confidence interval 0.22–0.61; r PFS non BRA: treatment 76%, placebo 60%, hazard ratio 0.57, confidence interval 0.39–0.82; OS hazard ratio: 0.77; OS confidence interval: 0.56–1.04; OS p value: 0.09; time to PSA progression hazard ratio: 0.51; time to PSA progression confidence interval: 0.37–0.71; time to PSA progression p value: < 0.0001; time to subsequent therapy hazard ratio: 0.51; time to subsequent therapy confidence interval: 0.38–0.70; time to subsequent therapy p value: < 0.0001 Read More | TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Read More | |
TALZENNA | metastatic prostate cancer | Phase 3 | 2026-06-01 | risk reduction: 52%; hazard ratio: 0.48; confidence interval: 0.36–0.65; p value: < 0.0001; r PFS three years treatment: 77%; r PFS three years placebo: 56%; median r PFS placebo: 46 months; r PFS BRA: treatment 77%, placebo 49%, hazard ratio 0.37, confidence interval 0.22–0.61; r PFS non BRA: treatment 76%, placebo 60%, hazard ratio 0.57, confidence interval 0.39–0.82; OS hazard ratio: 0.77; OS confidence interval: 0.56–1.04; OS p value: 0.09; time to PSA progression hazard ratio: 0.51; time to PSA progression confidence interval: 0.37–0.71; time to PSA progression p value: < 0.0001; time to subsequent therapy hazard ratio: 0.51; time to subsequent therapy confidence interval: 0.38–0.70; time to subsequent therapy p value: < 0.0001 Read More | TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PFE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PFE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PFE▼ -0.1%today
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizer and Astellas announced FDA approval for PADCEV combined with Keytruda as a treatment for muscle-invasive bladder cancer. This approval allows for neoadjuvant and adjuvant therapy in adult patients, irrespective of their eligibility for cisplatin. This marks a significant advancement in treatment options for this patient population.
Read more →PFE▼ -0.1%today
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board
BenchSci has appointed Dr. Mikael Dolsten as its first Chairman of the Board, effective June 2026. Dr. Dolsten, who previously served as Chief Scientific Officer at Pfizer, joined the board as a director in July 2025. His extensive experience in biopharma research is expected to guide BenchSci's future developments.
Read more →PFEPfizer Declares Third-Quarter 2026 Dividend
Pfizer has announced its dividend for the third quarter of 2026. This declaration is part of the company's ongoing commitment to returning value to its shareholders. Further details regarding the dividend amount and payment date were not provided in the announcement.
Read more →PFEFDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
The FDA has approved Pfizer's IBRANCE regimen for frontline maintenance treatment in patients with HR+, HER2+ metastatic breast cancer. This approval represents a significant advancement in therapeutic options for this patient population. The regimen aims to enhance treatment outcomes and provide hope for improved management of the disease.
Read more →PFEJavelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform
Javelin Biotech and Pfizer have announced a significant publication regarding clinical pharmacokinetic predictions. The study utilizes a multi-tissue chip platform, showcasing advancements in drug development methodologies. This collaboration highlights the ongoing efforts to enhance predictive models in clinical settings.
Read more →PFEPfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
Pfizer has announced an invitation for the public to view and listen to a webcast of its conference call with analysts scheduled for August 4. This event aims to provide insights into the company's performance and future strategies. The call will be accessible to the public, promoting transparency and engagement.
Read more →PFEPfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer has announced topline results from a Phase 3 trial of Sigvotatug Vedotin for patients with previously treated metastatic non-squamous non-small cell lung cancer. The details of the results and implications for treatment are currently not disclosed in the article. Further information may be expected in future communications.
Read more →PFEPfizer Announces Chief Financial Officer Transition
Pfizer has announced a transition in its Chief Financial Officer position. The company is expected to provide further details regarding the transition process and its implications for the organization. This change is part of Pfizer's ongoing efforts to enhance its leadership team.
Read more →PFEBio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors
Bio Usawa has appointed Dr. Aida Habtezion to its Board of Directors, marking a significant step in enhancing biomanufacturing capacity in Africa. Dr. Habtezion, a former Chief Medical Officer at Pfizer, brings a wealth of experience in medical science and biopharmaceutical leadership. Her role is expected to advance the company's mission of improving access to biologic medicines across the continent.
Read more →PFEU.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizer has received FDA approval for an expanded indication of HYMPAVZI, allowing its use in treating hemophilia A or B patients aged 12 and older with inhibitors, as well as pediatric patients aged 6 to 11. This approval aims to provide routine prophylaxis to prevent bleeding episodes, addressing significant medical needs in these populations.
Read more →PFERobust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer's Phase 2b trial for Berobenatide, a GLP-1 receptor agonist, demonstrated strong efficacy and a favorable tolerability profile. These results support the potential for a monthly dosing regimen, which could enhance patient compliance. The findings mark a significant advancement in the treatment options for patients.
Read more →PFETALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Pfizer announced positive results from the Phase 3 TALAPRO-3 study, showing that TALZENNA combined with XTANDI significantly improves radiographic progression-free survival in men with HRR gene-mutated metastatic prostate cancer. The combination demonstrated a 52% reduction in the risk of progression or death compared to placebo. The findings highlight the potential for this regimen to enhance patient outcomes in a challenging cancer population.
Read more →PFEPfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer's BRAFTOVI regimen has demonstrated significant efficacy in treating metastatic colorectal cancer, nearly doubling the median progression-free survival rate for patients. This advancement highlights the potential of BRAFTOVI as a key treatment option in oncology. The results from the clinical trials are expected to impact future treatment protocols.
Read more →PFESeven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer's analysis from the LORBRENA CROWN trial highlights the longest progression-free survival reported to date for patients with advanced non-small cell lung cancer (NSCLC). This seven-year analysis underscores the potential benefits of LORBRENA in extending survival rates for this patient population. The findings may influence future treatment protocols and patient management strategies.
Read more →PFEPfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer and Innovent Biologics have announced a global strategic collaboration focused on accelerating the development of innovative oncology medicines. This partnership aims to combine the strengths of both companies to enhance treatment options for cancer patients. The collaboration is expected to lead to significant advancements in oncology therapies.
Read more →PFEInnovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent Biologics and Pfizer have entered a strategic collaboration to develop 12 early-stage cancer medicines. The partnership combines Innovent's oncology expertise with Pfizer's global capabilities, allowing for co-development and commercialization of promising therapies. Innovent will initially lead Phase 1 development, with Pfizer taking over for later stages. The agreement includes substantial financial incentives, potentially reaching $10.5 billion.
Read more →PFEPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer has announced an invitation for the public to view and listen to a webcast of their discussion at an upcoming healthcare conference. This initiative aims to enhance transparency and engagement with stakeholders. Further details regarding the conference specifics were not provided in the announcement.
Read more →PFEPfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Pfizer has reported strong positive results from its Phase 2 trials for a pediatric pneumococcal vaccine. This advancement is expected to enhance immunization efforts among children, potentially leading to better health outcomes. The company is moving forward with its pivotal program, highlighting the importance of this vaccine in pediatric care.
Read more →PFEEuropean Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
The European Commission has granted approval for Pfizer's HYMPAVZI, a treatment for adults and adolescents suffering from Hemophilia A or B with inhibitors. This approval marks a notable advancement in the management of hemophilia, addressing a significant need within the patient population. The drug is expected to strengthen Pfizer's portfolio in the hemophilia market.
Read more →PFEFor the Reasons that Matter: A Multi-Spotlight Campaign Puts Adult Respiratory Health in Focus In conjunction with World Immunization Week, Pfizer Indonesia, together with healthcare professionals has launched "For the Reasons that Matter", a...
Pfizer Indonesia has launched the 'For the Reasons that Matter' campaign during World Immunization Week to enhance awareness of adult respiratory health. The initiative targets serious respiratory illnesses affecting adults, such as COVID-19 and influenza, and emphasizes the importance of preventive health measures. The campaign is being rolled out across Indonesia, Malaysia, Singapore, and the Philippines, aiming to bridge the gap between adults' health desires and their actions.
Read more →PFEg Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products (1) Pipeline Momentum Builds on Positive Phase 3
Pfizer reported a strong financial performance for the first quarter of 2026, with revenues reaching $14.5 billion, reflecting a 5% year-over-year increase. The significant growth was largely driven by a 22% rise in operational revenue from launched and acquired products. The company reaffirmed its full-year guidance, emphasizing robust pipeline momentum supported by positive Phase 3 results. However, Pfizer experienced declines in net income and adjusted earnings per share compared to the prior year, primarily due to reduced revenues from COVID-19 related products.
Read more →PFEPfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Pfizer has announced robust financial results for the first quarter, showcasing a strong performance that aligns with its strategic objectives. The company has also reaffirmed its guidance for 2026, indicating confidence in its future prospects. This positive outlook reflects Pfizer's ongoing commitment to growth and innovation in the biopharma sector.
Read more →PFEFor the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health In conjunction with World Immunisation Week, Pfizer Singapore, together with healthcare professionals, has launched "For the Reasons that Matter", a...
Pfizer Singapore has launched a multi-country campaign titled 'For the Reasons that Matter' to raise awareness about adult respiratory health. The initiative targets Singapore, Malaysia, Indonesia, and the Philippines, emphasizing the importance of discussing respiratory illnesses like COVID-19 and pneumonia. The campaign aims to bridge the gap between adults' health aspirations and their protective actions, particularly in light of the aging population in Singapore.
Read more →PFEFor the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health Pfizer Philippines, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult...
Pfizer Philippines has launched the 'For the Reasons that Matter' campaign to raise awareness about adult respiratory health across the Philippines, Malaysia, Indonesia, and Singapore. The initiative highlights the impact of serious respiratory illnesses like COVID-19 and pneumonia, particularly among older adults. The campaign aims to encourage proactive health conversations and actions to prevent these illnesses.
Read more →PFEPfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Pfizer has reported positive topline results from the Phase 3 MagnetisMM-5 study for ELREXFIO (elranatamab), a treatment for adults with relapsed or refractory multiple myeloma. The study indicated a statistically significant improvement in progression-free survival for patients who had received at least one prior treatment. This advancement highlights the potential of ELREXFIO in addressing unmet medical needs in this patient group.
Read more →PFEPfizer Reaches Three Settlement Agreements for VYNDAMAX
Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd regarding patent infringement lawsuits for VYNDAMAX. This agreement extends the patent expiry date to June 1, 2031, helping stabilize expected revenues until mid-2031. VYNDAMAX continues to lead the ATTR-CM market, providing significant benefits to patients.
Read more →PFEPfizer Declares Second-Quarter 2026 Dividend
Pfizer has announced its dividend for the second quarter of 2026. The declaration reflects the company's ongoing commitment to returning value to its shareholders. Further details about the dividend amount and payment date were not disclosed in the article.
Read more →PFEPfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
Pfizer Inc. will present significant data from its oncology pipeline at the ASCO Annual Meeting in June 2026. The company will share findings from over 40 research abstracts, including late-breaking sessions on therapies for various cancers. Key highlights include updates on treatments for lung, colorectal, prostate, and breast cancers, reinforcing Pfizer's leadership in oncology innovation.
Read more →PFEPfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
Pfizer Inc. has announced its virtual 2026 Annual Meeting of Shareholders scheduled for April 23, 2026. Shareholders can log in to participate and vote, with detailed instructions provided for accessing the meeting. Questions can be submitted in advance, and a replay will be available post-meeting.
Read more →PFEPfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
Pfizer has announced an invitation for the public to view and listen to a webcast of its conference call with analysts scheduled for May 5. This event aims to provide insights into the company's current status and future plans. Details about the webcast are expected to be shared closer to the date.
Read more →PFEPfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Pfizer and Valneva have reported positive topline results from the Phase 3 VALOR trial for their Lyme disease vaccine candidate, PF-07307405. The vaccine demonstrated an efficacy of 73.2% in reducing Lyme disease rates from 28 days after the fourth dose. This promising outcome highlights the potential of the vaccine in preventing Lyme disease among outdoor enthusiasts.
Read more →PFEPfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
Pfizer and Valneva announced positive results from the Phase 3 VALOR trial for their Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrating over 70% efficacy in preventing the disease in individuals aged five and older. The vaccine was well tolerated, and Pfizer intends to submit regulatory filings based on these encouraging results. The study highlights the urgent need for a Lyme disease vaccine, as there are currently no available options.
Read more →PFEPfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Pfizer announced positive topline results from the Phase 2 FOURLIGHT-1 study of atirmociclib, a CDK4 inhibitor, in patients with HR-positive, HER2-negative metastatic breast cancer. The study achieved its primary endpoint, showing significant improvement in progression-free survival. Atirmociclib demonstrated a manageable safety profile, with ongoing studies planned to further assess its efficacy in earlier treatment lines.
Read more →PFEPfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
Pfizer announced positive topline results from a Phase 2 study of tilrekimig in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, showing a significant increase in participants achieving EASI-75 at Week 16. Tilrekimig, a trispecific antibody, targets key inflammatory pathways and may offer improved efficacy over existing treatments. The drug was well-tolerated, with adverse event rates comparable to placebo.
Read more →PFEPADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Pfizer and Astellas announced positive results from the Phase 3 EV-304 trial, showing that the combination of PADCEV and Keytruda significantly reduces the risk of recurrence or death in patients with muscle-invasive bladder cancer. The treatment demonstrated a 47% reduction in risk compared to standard chemotherapy, with a notable pathological complete response rate. The findings suggest a potential shift away from traditional platinum-based chemotherapy as a standard treatment option.
Read more →PFEViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
ViiV Healthcare presented promising data on two investigational HIV treatments, VH184 and VH499, at the CROI 2026 conference. VH184, a third-generation integrase strand transfer inhibitor, shows potential for twice-yearly dosing with a favorable safety profile. VH499, a capsid inhibitor, also indicates potential for ultra long-acting dosing. Both therapies aim to improve treatment adherence for people living with HIV.
Read more →PFEViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
ViiV Healthcare announced positive 12-month data from the phase IIb EMBRACE study, showing that the investigational bNAb lotivibart (N6LS) maintained viral suppression in 94% of participants receiving it intravenously and 82% subcutaneously. The results support the potential for ultra long-acting treatment regimens and will be evaluated for a twice-yearly dosing interval. The study also noted high tolerability and acceptability among participants.
Read more →PFEU.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
Pfizer's BRAFTOVI combination therapy has received full FDA approval for treating adult patients with metastatic colorectal cancer harboring the BRAF V600E mutation. This decision is based on the positive outcomes from the Phase 3 BREAKWATER trial, which demonstrated significant improvements in progression-free and overall survival. The approval positions BRAFTOVI as a standard first-line treatment option, addressing a critical need in oncology.
Read more →PFEPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. is inviting the public to listen to a webcast featuring CEO Albert Bourla at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The webcast will be accessible via Pfizer's investor website, with a transcript and replay available shortly after the live event. This initiative underscores Pfizer's commitment to transparency and investor relations.
Read more →PFEViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
ViiV Healthcare presented innovative data on HIV treatment and prevention at CROI 2026, showcasing advancements in ultra long-acting therapies. Key highlights included the first third-generation integrase inhibitor, VH184, and long-term data from the EMBRACE study on lotivibart. The company emphasized its dedication to meeting the needs of the HIV community through ongoing research and development.
Read more →PFEPfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer announced positive topline results from Cohort 3 of the BREAKWATER trial, showing that the BRAFTOVI regimen significantly improves progression-free survival in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation. The results also indicate a clinically meaningful improvement in overall survival. The regimen remains investigational and will be submitted for FDA review.
Read more →PFEFDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
Pfizer announced that the FDA has granted Priority Review for its supplemental Biologics License Application for HYMPAVZI (marstacimab). This application aims to expand the treatment indications for hemophilia A or B patients aged 6 years and older, including those with inhibitors. If approved, HYMPAVZI would provide a convenient, once-weekly subcutaneous injection option for patients with significant medical needs.
Read more →PFEPfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
Pfizer has launched the TrumpRx program aimed at making over 30 medicines more affordable for Americans, offering discounts of up to 85%. This initiative is part of Pfizer's Most Favored Nation agreement with the U.S. government, which aims to reduce prescription costs. The program allows patients to self-pay for treatments, enhancing access to essential medications for millions.
Read more →PFEPfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
Pfizer announced positive topline results from the Phase 2b VESPER-3 study of PF-08653944, an ultra-long-acting injectable GLP-1 receptor agonist. The study demonstrated significant weight loss of up to 12.3% with monthly dosing, maintaining a favorable safety profile. The results support the continuation into Phase 3 trials, aiming to expand treatment options for obesity.
Read more →PFEPfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Pfizer Inc. reported its financial results for the fourth quarter and full year of 2025, showing a solid performance despite a slight revenue decline. The company reaffirmed its guidance for 2026, anticipating key study starts and continued investment for growth. Notably, operational revenue for the non-COVID portfolio grew by 6%, highlighting effective commercial execution.
Read more →PFEg Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late Stage Pipeline Advance
Pfizer reported solid financial results for 2025, boasting an operational revenue growth of 6% in its non-COVID portfolio. The company affirmed its 2026 guidance, projecting revenues between $59.5 billion to $62.5 billion, along with 20 pivotal study starts planned. Despite a slight year-over-year decline in overall revenues, the company highlighted strong EPS performance and continued investments in research and development. Strategic priorities for 2026 are defined, emphasizing growth opportunities amid industry challenges.
Read more →PFEPfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term Growth Reaffirms Full-Year 2025 Adjusted (1) Diluted EPS Gu
Pfizer has reaffirmed its full-year 2025 adjusted diluted EPS guidance while revising its revenue estimates to approximately $62 billion. For 2026, the company anticipates revenue in the range of $59.5 to $62.5 billion, reflecting a decrease in anticipated COVID-19 product sales and losses due to product exclusivity expirations. Adjusted diluted EPS for 2026 is expected to be between $2.80 and $3.00. Pfizer remains focused on investing in its pipeline and pursuing long-term growth despite the revenue challenges ahead.
Read more →PFETUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pfizer announced positive results from the Phase 3 HER2CLIMB-05 trial, showing that TUKYSA (tucatinib) combined with trastuzumab and pertuzumab significantly extends median progression-free survival in patients with HER2-positive metastatic breast cancer. The treatment demonstrated a manageable safety profile, although overall survival data remains immature. These findings suggest a promising new approach for first-line maintenance therapy.
Read more →PFEHYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
Pfizer's Phase 3 BASIS study results show that HYMPAVZI (marstacimab) significantly reduces bleeding episodes in adults and adolescents with hemophilia A or B with inhibitors. The treatment demonstrated a 93% reduction in bleeding compared to on-demand therapy and is administered via a simple once-weekly injection. The findings were presented at the ASH Annual Meeting and submitted for FDA and EMA review.
Read more →PFEg Pfizer Reports Solid Third-Quarter 2025 Results Raises and Narrows 2025 EPS Guidance Focused Execution Delivers Strong EPS Performance Landmark Agreement Reached with U.S. Government Provides Longer-Term Business Clari
Pfizer Inc. has reported its third-quarter financial results for 2025, revealing revenues of $16.7 billion, which represents a 6% year-over-year decline. The company raised its guidance for adjusted diluted earnings per share, now expected to be between $3.00 and $3.15, reflecting confidence in its financial strategy. Key factors influencing revenue include a strong performance in its non-COVID portfolio despite challenges in COVID-19 product sales. Furthermore, Pfizer secured a landmark agreement with the U.S. government, enhancing long-term business clarity.
Read more →PFE▲ +5.2%on this news
g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R D Pipeline Expanded Programs On Track to Deliver Net C
Pfizer Inc. reported strong financial results for the second quarter of 2025, achieving revenues of $14.7 billion, a 10% increase from the previous year. The company also raised its full-year adjusted diluted EPS guidance to between $2.90 and $3.10, reflecting confidence in ongoing operational efficiencies and cost improvement initiatives. Key growth drivers included strong sales from products like Vyndaqel and Comirnaty. Despite these positives, Pfizer faced challenges with increased manufacturer discounts impacting several product revenues.
Read more →PFEInternational and Regional Experts Focus on RSV Prevention at Pfizer MERA Maternal Immunization Summit: Born Ready More than 80 international and regional healthcare experts have convened at the Pfizer MERA Maternal Immunization Summit: Born Ready to discuss...
The Pfizer MERA Maternal Immunization Summit convened over 80 healthcare experts in Cairo to focus on maternal immunization against respiratory syncytial virus (RSV). Discussions included the significant impact of RSV on neonatal health, the role of maternal antibodies, and addressing challenges to adopting maternal vaccination. Experts emphasized the importance of increasing awareness and collaboration among healthcare providers to enhance immunization programs, ultimately aiming to better protect newborns from this prevalent virus. Pfizer underscored its ongoing commitment to vaccine development as a key element of public health.
Read more →PFEg Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R D Organizati
Pfizer Inc. reported its first-quarter financial results for 2025, revealing revenues of $13.7 billion and an adjusted diluted EPS of $0.92, marking a 12% increase. The company reaffirmed its 2025 financial guidance, indicating optimism in exceeding cost savings targets during ongoing operational efficiencies. However, despite the strong performance in adjusted income, overall revenues declined by 8% compared to the previous year, largely impacted by significant drops in Paxlovid sales due to decreased COVID-19 infections. Additionally, the company faces challenges from heightened manufacturer discounts stemming from recent Medicare reforms.
Read more →PFEPfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth - Excluding Contributions from Paxlovid and Comirnaty (1)
Pfizer reported its full-year 2024 financial results, achieving revenues of $63.6 billion with a 7% year-over-year operational growth. The company reaffirmed its guidance for 2025, targeting revenues between $61 billion and $64 billion. Leadership highlighted strong commercial performance, particularly from the non-COVID-19 product lines, while acknowledging challenges with Comirnaty revenues due to the decline in COVID-19 vaccination rates. Overall, Pfizer continues to focus on cost savings and enhancing shareholder value through improved operational efficiency.
Read more →PFEPfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
Pfizer has provided its financial guidance for 2025 while reaffirming its forecast for 2024. The company anticipates 2025 revenues between $61 billion and $64 billion, factoring in an expected unfavorable impact of $1 billion from the Inflation Reduction Act. Additionally, Pfizer expects a growth in adjusted diluted EPS by 10% to 18% compared to 2024. The company has achieved significant cost savings and aims to continue optimizing its manufacturing processes to improve margins.
Read more →PFEPfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate ...
Pfizer's 20-valent Pneumococcal Conjugate Vaccine (PCV20) has been approved by the Hong Kong Department of Health for use in infants, children, and adolescents aged 6 weeks to under 18 years. This vaccine offers protection against 20 serotypes of Streptococcus pneumoniae, including those associated with antibiotic resistance. The approval builds on Pfizer's legacy in developing pneumococcal vaccines and aims to reduce pneumonia-related deaths in the pediatric population.
Read more →PFE輝瑞20價肺炎球菌結合疫苗獲香港衛生署批准適用於嬰幼兒及兒童 輝瑞今日宣布香港衛生署已批准該公司的20價肺炎球菌結合疫苗，用於6週至未滿18歲的嬰幼兒、兒童及青少年作主動免疫，以對抗由肺炎鏈球菌引致的侵入性疾病、肺炎，及急性中耳炎。[iii]...
Pfizer has announced the approval of its 20-valent pneumococcal conjugate vaccine, aimed at infants and children under 18 years old. This vaccine is designed to combat severe infections caused by various strains of pneumococcus. The approval marks a significant advancement in pediatric healthcare, potentially reducing mortality rates associated with pneumococcal diseases.
Read more →PFEInternational and Regional Experts Address the Role of Vaccines in Disease Management during Pfizer MERA Vaccines Summit 2024 International and regional experts addressed more than 180 regional physicians and healthcare professionals during the annual vaccines summit, hosted ...
The Pfizer MERA Vaccines Summit 2024, held in Dubai, gathered over 180 healthcare professionals to discuss the impact of vaccinations on public health. Key topics included the burden of pneumococcal disease, the evolution of vaccines, and strategies to combat antimicrobial resistance. Speakers emphasized the importance of vaccination for vulnerable populations and collaborative efforts between the medical community and vaccine developers. Pfizer reiterated its commitment to advancing vaccine research and development, aiming to protect global health through innovative solutions.
Read more →PFEPfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year
Pfizer has reported strong financial results for the third quarter of 2024, showcasing a 32% year-over-year revenue growth, which has prompted the company to raise its full-year revenue guidance to between $61.0 and $64.0 billion. The company's performance was bolstered by significant contributions from Oncology products and heightened demand for Paxlovid during a COVID-19 resurgence. Meanwhile, strategic cost reduction initiatives are expected to yield net savings of at least $5.5 billion. However, there are concerns regarding revenue dependence on COVID-related products and potential declines associated with the withdrawal of specific treatments.
Read more →PFETim Buckley Elected to Pfizer's Board of Directors
Pfizer Inc. has announced the election of Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately. Buckley, aged 55, will also serve on the Governance and Sustainability Committee as well as the Audit Committee, increasing the Board's total to 14 members. His previous experience includes a long tenure at Vanguard, where he held various senior leadership roles, culminating in his position as Chairman and CEO. Pfizer's Chairman and CEO expressed confidence that Buckley's expertise will add value to the company.
Read more →PFEInaugural Health and Wellbeing Forum Discussed about Co-creating Healthier Hong Kong for all Pfizer Hong Kong held its inaugural "Health & Well-being Forum" to discuss important issues on social health equity and mental health, bringing...
Pfizer Hong Kong hosted its inaugural 'Health & Well-being Forum' to address social health equity and mental health issues. The event gathered over 60 representatives from various sectors to discuss the importance of equitable healthcare access. Pfizer aims to facilitate discussions that prompt policymakers to implement health-promoting policies, reflecting their commitment to community health.
Read more →PFE首個共「健」未來研討會 探討不同可能性以達致健康公平最大化 今天，輝瑞香港首次以探討社會健康公平、精神健康等重要議題，舉行「共『健』未來」研討會，滙聚超過60位本地病人組織代表、學者、醫護界代表、議員和其他持份者等參與是次活動，從不同角度出發，集思廣益，共同探討如何為香港建設一個更健康的未來。...
Pfizer hosted a significant health symposium in Hong Kong, focusing on health equity and mental health. The event gathered over 60 participants, including healthcare professionals and community representatives, to discuss strategies for enhancing health services. The symposium aimed to foster collaboration and address the diverse needs of the community, promoting a more inclusive healthcare environment.
Read more →PFEPfizer Appoints Elif Aral as Regional President for the Middle East, Russia & Africa Pfizer announces the appointment of Elif Aral as Regional President for Middle East, Russia, and Africa (MERA) effective September 2024 to spearhead...
Pfizer announced the appointment of Elif Aral as Regional President for the Middle East, Russia, and Africa (MERA), effective September 2024. In this role, she will oversee strategic initiatives aimed at improving healthcare access and equity in the region. Elif, who has been with Pfizer since 1995, has a notable history of leadership in various capacities, including her recent work on the 'An Accord for a Healthier World' initiative targeting health inequities. She aims to leverage Pfizer's strengths to ensure accessibility to its innovative treatments across MERA communities.
Read more →PFEPfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance Second-Quarter Performance Driven by Focused Commercial Execution Raises Full-Year 2024 Revenue Guidance (1) to a Range of $59.5 to $62.5 Billion
Pfizer Inc. reported strong financial results for the second quarter of 2024, with revenues reaching $13.3 billion, up 3% operationally year-over-year. The company also raised its full-year guidance for 2024, anticipating revenues between $59.5 and $62.5 billion, driven by robust performance in its commercial execution. Significant growth was observed in Pfizer's non-COVID product revenues, which rose 14% operationally. However, the company reported a diluted EPS of $0.01, a notable decline from the previous year, due in part to one-time costs related to a new manufacturing optimization program.
Read more →PFEDear Colleague, On Wednesday, July 24, the Compensation Committee of the Board of Directors approved modifications to the 2022 and 2023 5-year Total Shareholder Return Units (TSRUs) to encourage your retention, further m
On July 24, Pfizer's Compensation Committee approved modifications to the 2022 and 2023 5-year Total Shareholder Return Units (TSRUs) to encourage employee retention and bolster commitment to long-term performance. The changes entail extending the TSRUs by two years, providing employees more time to benefit from potential stock price recovery. This initiative aims to align the interests of employees with those of shareholders, particularly following a downturn in stock performance linked to disappointing COVID-19 vaccination rates. Employees have the option to voluntarily accept these modifications to benefit from enhanced vesting terms.
Read more →PFEPfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities in Hong Kong and...
Pfizer has announced the availability of its bivalent RSV prefusion F vaccine in Hong Kong, approved for use in older adults and infants. This single-dose vaccine addresses lower respiratory tract disease caused by RSV A and B. It represents a significant advancement in protecting vulnerable populations against RSV, which poses serious health risks.
Read more →PFECyrus Taraporevala Elected to Pfizer's Board of Directors
Cyrus Taraporevala has been elected to Pfizer's Board of Directors, effective immediately. He will also join the Audit Committee and Compensation Committee. Taraporevala previously served as CEO at State Street Global Advisors and has extensive experience in asset management. His leadership roles in various financial institutions are expected to enhance Pfizer's Board dynamics.
Read more →PFEPfizer Reflects on 175-Year Global Legacy and Decades of Regional Breakthroughs Pfizer commemorated its 175-year anniversary in Dubai on June 11, by reflecting on the significant contributions made in the global and regional...
Pfizer celebrated its 175-year legacy in Dubai, reflecting on its contributions to healthcare and announcing future initiatives. In 2023, the company launched 32 products in the MERA region and reached over 45 million patients, solidifying its regional impact. Pfizer's acquisition of Seagen has strengthened its oncology portfolio, with a strong commitment to patient access through innovative collaborations. Moving forward, the company aims to leverage AI in enhancing patient outcomes and expand its oncology offerings while focusing on diversity and inclusion efforts within the healthcare sector.
Read more →PFEPfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) The first...
Pfizer has received marketing authorization from the Hong Kong Department of Health for its bivalent RSV vaccine, designed for older adults and infants through maternal immunization. This vaccine, the first of its kind, targets both RSV A and B and is expected to be available in Macau by June 2024 and in Hong Kong by August 2024. Clinical trials have shown promising results in terms of safety and efficacy.
Read more →PFE輝瑞獲香港衛生署批准推出呼吸道合胞病毒（RSV）疫苗 輝瑞今天宣布獲香港衛生署批准推出用於針對由RSV引起的下呼吸道疾病（LRTD）和嚴重LRTD的 RSV融合前F蛋白（RSVpreF）二價疫苗，為60歲或以上長者及初生至六個月大嬰兒提供保護*。...
Pfizer has announced its bivalent RSV vaccine, designed to protect older adults and infants from respiratory syncytial virus (RSV). The vaccine targets RSV A and B subtypes and is expected to be available in Hong Kong by August 2024. Clinical trials indicate its effectiveness in preventing RSV-related lower respiratory tract disease.
Read more →PFE▲ +6.1%on this news
Pfizer Reports First-Quarter 2024 Results Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities First-Quarter 2024 Revenues of $14.9 Billion - Expected Decline in
Pfizer reported its first-quarter results for 2024, revealing revenues of $14.9 billion, reflecting a 20% decline year-over-year due primarily to lower demand for Comirnaty and Paxlovid. However, the company noted an 11% operational revenue growth from its non-COVID portfolio, highlighting strong performance in several key products. Pfizer's adjusted diluted EPS guidance was raised, signaling confidence in continued growth amid its cost realignment efforts. Despite challenges from COVID-related products, Pfizer is positioning itself for positive momentum moving forward.
Read more →PFEPfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance 2023 Sets Stage for Future Growth Potential Completed Seagen Acquisition, Creating World-Class Oncology Organization Launched Signific
Pfizer Inc. reported its financial results for full-year 2023, indicating total revenues of $58.5 billion despite a sharp operational decline of 41% driven by reduced sales from its COVID-19 products. However, excluding these products, the company's revenues showed a 7% operational growth. Pfizer reaffirmed its financial guidance for 2024, projecting revenues between $58.5 to $61.5 billion and adjusted diluted EPS of $2.05 to $2.25. The completion of the Seagen acquisition is highlighted as a key factor in enhancing Pfizer's oncology position, with expectations for future growth bolstered by new product launches and cost-saving measures.
Read more →PFEPfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Pfizer Inc. has advised its shareholders to reject a mini-tender offer from TRC Capital Investment Corporation due to the offer being below market value. The proposed price of $27.35 per share is approximately 4.4% lower than Pfizer's closing stock price preceding the offer. Pfizer also warns that mini-tender offers generally provide less protection under U.S. securities laws and encourages shareholders to withdraw any shares already tendered if they wish. The offer is set to expire on January 30, 2024, at 12:01 a.m. New York City time.
Read more →PFEPfizer Completes Acquisition of Seagen
Pfizer has successfully completed its acquisition of Seagen, a biotech company known for its cancer therapies, for approximately $43 billion. This acquisition enhances Pfizer's oncology portfolio, adding multiple innovative medicines and doubling its oncology pipeline. With Seagen's advanced ADC technology, the company aims to transform cancer treatment, aligning with its long-term growth strategy. In response to FTC concerns, Pfizer has committed to donating royalties from Bavencio sales to cancer research initiatives.
Read more →PFEPfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Pfizer has announced it received all required regulatory approvals to complete its acquisition of Seagen, with the expected closure on December 14, 2023. To enhance its focus in oncology, Pfizer will reorganize its commercial structure, creating the Pfizer Oncology Division and appointing new leadership roles. The company has also pledged to donate rights to royalties from Bavencio sales to the American Association for Cancer Research in response to FTC concerns. Angela Hwang, the outgoing Chief Commercial Officer, will assist in the transition following her nearly three-decade tenure at Pfizer.
Read more →PFEThe Arab International Women's Forum and Pfizer launch 'DEI by Design' report with recommendations on embedding diversity into MENA health Pfizer and the Arab International Women Forum (AIWF) launched the 'DEI by Design' report containing insights and recommendations about how women's...
Pfizer and the Arab International Women Forum (AIWF) have launched the 'DEI by Design' report, which outlines strategies to enhance women's leadership in the healthcare sector across the Middle East and North Africa (MENA). The report is the culmination of a series of discussions involving health professionals that highlighted the importance of diversity and mentorship. Focused on post-COVID challenges, the initiative seeks to bridge the gender gap in healthcare leadership and improve health outcomes. The findings aim to inspire stakeholders to take actionable steps towards embedding diversity in regional health ecosystems.
Read more →PFEPfizer Holds MERA Vaccines Summit to Discuss the Impact of Vaccines on Controlling Diseases in the Region Pfizer Middle East, Russia and Africa (MERA) hosted the MERA Vaccines Summit, welcoming more than 100 physicians and healthcare professionals from...
Pfizer Middle East, Russia and Africa (MERA) hosted the MERA Vaccines Summit in Dubai, bringing together over 100 healthcare professionals to discuss the impact of vaccines on disease control. The event featured expert discussions on the public health benefits of vaccination and recommendations for various patient populations. Key topics included the importance of maternal vaccines and strategies for vaccination during high-risk events to prevent disease outbreaks, particularly in light of recent global health challenges.
Read more →PFEUpdates Full-Year 2023 Guidance
Pfizer Inc. has amended its supply agreement with the U.S. government for the antiviral drug Paxlovid, aiming to transition to commercial sales in January 2024. The company has updated its 2023 revenue guidance to $58.0 to $61.0 billion, lowering expectations due to reduced demand for COVID products like Comirnaty and Paxlovid. A patient assistance program will continue to offer Paxlovid free of charge to qualifying patients through 2024, while Pfizer prepares to negotiate pricing for commercially insured patients. Furthermore, the company is implementing a cost realignment program to achieve significant savings in the coming years.
Read more →PFEPfizer Reports Third-Quarter 2023 Results Third-Quarter 2023 Revenues of $13.2 Billion - Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues - Revenues fo
Pfizer reported disappointing third-quarter 2023 results, revealing revenues of $13.2 billion, a 42% drop compared to the prior year. The decrease was driven largely by expected declines in Paxlovid and Comirnaty revenues, although non-COVID product revenues showed a 10% operational increase. The company reaffirmed its full-year revenue guidance and highlighted successful launches of new products. However, significant non-cash inventory write-offs negatively impacted profits.
Read more →PFEPfizer Reports Second-Quarter 2023 Results Second-Quarter 2023 Revenues of $12.7 Billion - Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 53% Operational Decrease in Second-Quarter 2023 Revenues - Second-Q
Pfizer reported its second-quarter 2023 results, revealing a significant operational decrease in revenues by 53%, primarily due to declining earnings from Paxlovid and Comirnaty. The company expects a revenue guidance range of $67 to $70 billion for the year while maintaining its adjusted diluted EPS outlook. Despite this downturn, Pfizer achieved 5% operational revenue growth when excluding COVID-related products and is progressing on multiple product launches. There are challenges anticipated in sustaining revenue for core products, influencing overall financial health as the market adapts to changing dynamics.
Read more →PFEPfizer Reports First-Quarter 2023 Results First-Quarter 2023 Revenues of $18.3 Billion - Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues - First-Quarter 2023 Revenu
Pfizer reported first-quarter 2023 revenues of $18.3 billion, a 26% operational decline primarily driven by expected drops in its COVID-19 products, Comirnaty and Paxlovid. While the company reaffirmed its full-year guidance and saw a 5% operational revenue increase excluding these products, its diluted earnings per share fell by 29% year-over-year. CEO Dr. Albert Bourla highlighted significant progress towards new product launches and announced plans for the acquisition of Seagen, aimed at enhancing Pfizer's oncology capabilities. The company's outlook continues to reflect challenges from decreased COVID-19 product sales and anticipated operational growth in 2023.
Read more →PFEPfizer Invests $43 Billion to Battle Cancer Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer s position as a leadi
Pfizer announced a definitive agreement to acquire Seagen for $229 per share, totalling around $43 billion. This merger is expected to bolster Pfizer's position in oncology, combining Seagen's advanced antibody-drug conjugate technology with Pfizer's extensive resources. Projected revenues from Seagen could exceed $10 billion by 2030, although the deal requires shareholder and regulatory approvals. Pfizer aims to finance the acquisition primarily via long-term debt and anticipates achieving significant cost efficiencies post-transaction.
Read more →PFEPFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth - Excluding Contributi
Pfizer reported a record full-year revenue of $100.3 billion for 2022, reflecting a 30% operational growth compared to the previous year. The company provided guidance for 2023, expecting revenues to decline to between $67.0 billion and $71.0 billion, predominantly due to decreased sales from COVID-19 products like Comirnaty and Paxlovid. However, Pfizer anticipates operational growth of 7% to 9% excluding COVID-19 products and plans significant investments in research and development to support upcoming product launches. The diluted earnings per share for 2022 reached an all-time high of $6.58, but is expected to decline in 2023.
Read more →PFEPFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK Solid Third-Quarter 2022 Revenues of $22.6 Billion - Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Op
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK Solid Third-Quarter 2022 Revenues of $22.6 Billion -Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally -Excluding Contributions from Paxlovid and Com
Read more →PFEPadecimientos de la piel, la 4ª causa de enfermedades en el ser humano Los padecimientos de la piel representan la 4ª causa de enfermedades no mortales, de acuerdo con el estudio Dermatología Médica Aumento del...
CIUDAD DE MÉXICO , 20 de septiembre de 2022 /PRNewswire/ -- Los padecimientos de la piel representan la 4ª causa de enfermedades no mortales, de acuerdo con el estudio Dermatología Médica Aumento del conocimiento y acceso a la atención en América Latina: Casos de estudio en derma
Read more →PFEPFIZER REPORTS SECOND-QUARTER 2022 RESULTS Second-Quarter 2022 Revenues of $27.7 Billion, Reflecting 53% Operational Growth, Driven Primarily by Strong Contributions from Paxlovid and Comirnaty (1) Second-Quarter 2022 Re
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS Second-Quarter 2022 Revenues of $27.7 Billion, Reflecting 53% Operational Growth, Driven Primarily by Strong Contributions from Paxlovid and Comirnaty(1) Second-Quarter 2022 Reported Diluted EPS(2) of $1.73, Reflecting 77% Growth Over
Read more →PFEPfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries - Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45...
- Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries. - Rwanda , Ghana , Malawi , Senegal and Uganda are the first five countries to commit to join the Accord.
Read more →PFEPfizer to Acquire Biohaven Pharmaceuticals
Pfizer to Acquire Biohaven Pharmaceuticals Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer s innovative Internal Medicine pipeline to drive enhanced growt
Read more →PFEPFIZER REPORTS FIRST-QUARTER 2022 RESULTS First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Increased 2% Operationally First
PFIZER REPORTS FIRST-QUARTER 2022 RESULTS First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted
Read more →PFEPFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 6% Operationally
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion Fourth-Quarter 2021 Revenues of $23.8 Bil
Read more →PFEPfizer Announces Retirement of Chief Financial Officer
For Immediate Release November 17, 2021 Media Contact PfizerMediaRelations Pfizer.com +1 (212) 733-1226 Investor Contact IR Pfizer.com +1 (212) 733-4848 Pfizer Announces Retirement of Chief Financial Officer Mike McDermott named EVP Chief Global Supply Officer NEW YORK, Nov
Read more →PFEPFIZER REPORTS THIRD-QUARTER 2021 RESULTS Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth Excluding Comirnaty (1) , Revenues Grew 7% Operationally to $11.1 Billion Third-Quarter 2021 Repo
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth Excluding Comirnaty(1), Revenues Grew 7% Operationally to $11.1 Billion Third-Quarter 2021 Reported Diluted EPS(2) of $1.42, Adjusted Diluted EPS(3) of $1.
Read more →PFEPFIZER REPORTS SECOND-QUARTER 2021 RESULTS Second-Quarter 2021 Revenues of $19.0 Billion, Reflecting 86% Operational Growth Excluding BNT162b2 (1) , Revenues Grew 10% Operationally to $11.1 Billion The 10% Operational Gr
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS Second-Quarter 2021 Revenues of $19.0 Billion, Reflecting 86% Operational Growth Excluding BNT162b2(1), Revenues Grew 10% Operationally to $11.1 Billion The 10% Operational Growth Excluding BNT162b2(1) in Second-Quarter 2021 Builds on
Read more →PFEPFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth Excluding Revenues for BNT162b2 of $3.5 Billion, Revenues Grew 8% Operationally Including a
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth Excluding Revenues for BNT162b2 of $3.5 Billion, Revenues Grew 8% Operationally Including a Negative 5% Impact from Pricing First-Quarter 2021 Report
Read more →PFEPFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS Upjohn Business (1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted (2) Result
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS Upjohn Business(1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted(2) Results Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclu
Read more →PFENovos episódios do canal de podcasts Eu Doutor@ trazem reflexões sobre a vida e a carreira dos médicos Mesmo com o aumento das tarefas administrativas e as cargas horárias excessivas, os médicos se sacrificam pelo bem-estar da população. Mas, por trás...
SÃO PAULO, 15 de abril de 2020 /PRNewswire/ -- Mesmo com o aumento das tarefas administrativas e as cargas horárias excessivas, os médicos se sacrificam pelo bem-estar da população. Mas, por trás de cada profissional, há um ser humano, que exige atenção e cuidados com a saúde fís
Read more →PFENovo canal de podcasts Eu Doutor@ discute dilemas profissionais e pessoais dos médicos Com o aumento das tarefas administrativas e cargas horárias excessivas, muitos médicos sofrem em silêncio: uma revisão da literatura norte-americana...
SÃO PAULO, 17 de março de 2020 /PRNewswire/ -- Com o aumento das tarefas administrativas e cargas horárias excessivas, muitos médicos sofrem em silêncio: uma revisão da literatura norte-americana realizada pelo MEDLINE e pelo PubMed 1 revelou que a taxa de suicídio entre médicos
Read more →PFEColetivo Pink 2019: Festival de Arte e Cultura de São Paulo e exposição de fotos com de 30 pacientes de câncer de mama estão em cartaz na Casa das Rosas Um homem e 29 mulheres diagnosticados com câncer de mama compõem o elenco das vidas retratadas nos painéis da exposição Artemisa: Frida, a coragem do ...
SÃO PAULO, 10 de outubro de 2019 /PRNewswire/ -- Um homem e 29 mulheres diagnosticados com câncer de mama compõem o elenco das vidas retratadas nos painéis da exposição Artemisa: Frida, a coragem do Pink no Outubro Rosa , que ficará em cartaz até o dia 20 de outubro, na Casa das
Read more →PFEMovimento Desafio de Fôlego mobiliza artistas no combate ao câncer de pulmão O fôlego é fundamental para todos, nas mais diversas atividades. Mas, para quem vive de cantar, a saúde dos pulmões tem prioridade. Por isso, no Mês...
SÃO PAULO, 9 de agosto de 2019 /PRNewswire/ -- O fôlego é fundamental para todos, nas mais diversas atividades. Mas, para quem vive de cantar, a saúde dos pulmões tem prioridade. Por isso, no Mês de Conscientização do Câncer de Pulmão, grandes nomes da música brasileira foram des
Read more →PFEPediatras lançam cartilha digital para responder às principais dúvidas dos pais sobre saúde infantil Com foco no combate às fake news em saúde infantil, a campanha Mais que um Palpite chega a um ano de atividades nas redes sociais com mais de 21 mil...
SÃO PAULO, 19 de junho de 2019 /PRNewswire/ -- Com foco no combate às fake news em saúde infantil, a campanha Mais que um Palpite chega a um ano de atividades nas redes sociais com mais de 21 mil fãs em seus canais (Facebook e Instagram) e milhares de comentários no ambiente on-l
Read more →PFEÁrvores viram gente na Avenida Paulista para dar visibilidade a pacientes raros De quem será esse rosto? Muitos se farão essa pergunta ao passar pela altura do número 1.853 da Avenida Paulista, entre 14 e 16 de junho. Nesse...
Nas proximidades do Dia de Conscientização da PAF, em 16 de junho, ação propõe uma pausa no ritmo frenético da cidade para discutir a doença, que se manifesta em adultos jovens e pode levar à morte em poucos anos SÃO PAULO, 14 de junho de 2019 /PRNewswire/ -- De quem será esse r
Read more →PFEAnvisa estende aprovação de medicamento inovador para doenças inflamatórias autoimunes A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação de Xeljanz (citrato de tofacitinibe), desenvolvido pela...
SÃO PAULO, 9 de maio de 2019 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação de Xeljanz (citrato de tofacitinibe), desenvolvido pela Pfizer. A partir de agora o medicamento poderá ser utilizado por pacientes com colite ulce
Read more →PFELiderado por brasileiro, estudo pode mudar a conduta clínica para portadores de arritmia cardíaca e enfarte Um estudo recém-publicado pela revista científica New England Journal of Medicine, liderado pelo médico brasileiro Renato Deláscio Lopes, professor...
SÃO PAULO, 8 de maio de 2019 /PRNewswire/ -- Um estudo recém-publicado pela revista científica New England Journal of Medicine , liderado pelo médico brasileiro Renato Deláscio Lopes, professor na Divisão de Cardiologia da Duke University (EUA), pode impactar as diretrizes de tra
Read more →PFEPrograma da ONU apoiado pela Pfizer recebe inscrições até 30 de abril para projetos de desenvolvimento sustentável Estão abertas as inscrições para a 3ª edição do Programa Accelerate2030 promovido no Brasil e em outros 15 países pelo Programa da Nações Unidas para ...
SÃO PAULO, 17 de abril de 2019 /PRNewswire/ -- Estão abertas as inscrições para a 3ª edição do Programa Accelerate2030 promovido no Brasil e em outros 15 países pelo Programa da Nações Unidas para o Desenvolvimento (PNUD), órgão da ONU cujo propósito é promover o desenvolvimento
Read more →PFEAnticoncepcional inovador da Pfizer, com mecanismo de autoaplicação trimestral, chega ao Brasil Primeiro anticoncepcional com sistema de autoaplicação trimestral aprovado no Brasil, Sayana (acetato de medroxiprogesterona) acaba de chegar ao...
SÃO PAULO, 18 de março de 2019 /PRNewswire/ -- Primeiro anticoncepcional com sistema de autoaplicação trimestral aprovado no Brasil, Sayana (acetato de medroxiprogesterona) acaba de chegar ao mercado nacional. Comercializado pela Pfizer, o produto apresenta uma opção mais cômoda
Read more →PFEBrasil celebra primeiro Dia Nacional das Doenças Raras em meio a desafios Hoje, 28 de fevereiro, o Brasil celebra seu primeiro Dia Nacional de Doenças Raras. A lei que oficializa a efeméride representa mais um avanço no...
SÃO PAULO, 28 de fevereiro de 2019 /PRNewswire/ -- Hoje, 28 de fevereiro, o Brasil celebra seu primeiro Dia Nacional de Doenças Raras. A lei que oficializa a efeméride representa mais um avanço no apoio a esses pacientes, um movimento que ganhou força a partir de 2014, com a Polí
Read more →PFESUS passa a oferecer medicamento inovador para doença reumática A partir de agora, a rede pública passa a distribuir Xeljanz (citrato de tofacitinibe), da Pfizer, indicado para o tratamento de pacientes adultos...
SÃO PAULO, 21 de janeiro de 2019 /PRNewswire/ -- A partir de agora, a rede pública passa a distribuir Xeljanz (citrato de tofacitinibe), da Pfizer, indicado para o tratamento de pacientes adultos com artrite reumatoide moderada a grave. No final de dezembro, a companhia entregou
Read more →PFEGoverno avalia inclusão no SUS de vacina que amplia a proteção contra pneumonia bacteriana em pacientes de risco A Comissão Nacional de Incorporação de Tecnologias no SUS (Conitec) abriu consulta pública para conhecer a opinião da população sobre a inclusão na...
SÃO PAULO, 7 de dezembro de 2018 /PRNewswire/ -- A Comissão Nacional de Incorporação de Tecnologias no SUS (Conitec) abriu consulta pública para conhecer a opinião da população sobre a inclusão na rede pública, para grupos de pacientes de risco acima de 5 anos, da vacina pneumocó
Read more →PFECampanha digital da Pfizer alerta para uso consciente de antibióticos Em muitos países, antibióticos potentes usados para tratar infecções causadas pela bactéria Klebsiella pneumoniae, encontrada na flora intestinal...
SÃO PAULO, 14 de novembro de 2018 /PRNewswire/ -- Em muitos países, antibióticos potentes usados para tratar infecções causadas pela bactéria Klebsiella pneumoniae, encontrada na flora intestinal humana, já não funcionam. Esse dado, divulgado no primeiro relatório global sobre a
Read more →PFEPfizer's New Report Shows How Behavioural Science Can Help Boost Preventative Healthcare Measures Released today, a new report based on research by the Economist Intelligence Unit (EIU) and sponsored by Pfizer Vaccines assesses why, despite the...
PARIS , July 31, 2018 /PRNewswire/ -- Report key findings and recommendations The report has been released on the back of a webinar hosted on the 4 th July by Economist Events. A panel of multi-disciplinary experts came together to discuss the findings of the report and what ne
Read more →PFEAnvisa aprova medicamento inovador da Pfizer para reposição hormonal A Anvisa acaba de aprovar o medicamento Duavive (estrogênios conjugados/ acetato de bazedoxifeno), da Pfizer, para o tratamento de sintomas...
SÃO PAULO, 6 de junho de 2018 /PRNewswire/ -- A Anvisa acaba de aprovar o medicamento Duavive (estrogênios conjugados/ acetato de bazedoxifeno), da Pfizer, para o tratamento de sintomas vasomotores moderados a graves associados à menopausa. Esses sintomas, que estão associados à
Read more →PFEAnvisa estende indicação de vacina contra meningite da Pfizer A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação da vacina Nimenrix, da Pfizer, recomendada para prevenção da ...
SÃO PAULO, 4 de junho de 2018 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação da vacina Nimenrix, da Pfizer, recomendada para prevenção da doença meningocócica invasiva, em especial a meningite, provocada pelos sorogrupos A
Read more →PFEPfizer lança no Brasil medicamento inovador para câncer de mama A Pfizer acaba de lançar o medicamento Ibrance (palbociclibe), uma terapia inovadora para o tratamento do câncer de mama metastático do tipo hormônio ...
SÃO PAULO, 23 de maio de 2018 /PRNewswire/ -- A Pfizer acaba de lançar o medicamento Ibrance (palbociclibe), uma terapia inovadora para o tratamento do câncer de mama metastático do tipo hormônio receptor positivo (HR+) e HER2- em mulheres na pós-menopausa. Ou seja, são pacientes
Read more →PFEInstituições brasileiras recebem executivos da Pfizer de diferentes países para trabalho voluntário Uma comitiva formada por nove executivos da Pfizer, vindos de diferentes países, acaba de desembarcar em São Paulo para auxiliar organizações não...
SÃO PAULO, 21 de maio de 2018 /PRNewswire/ -- Uma comitiva formada por nove executivos da Pfizer, vindos de diferentes países, acaba de desembarcar em São Paulo para auxiliar organizações não governamentais (ONGs) da cidade no desenvolvimento de soluções que consolidem as operaçõ
Read more →PFEAnvisa aprova nova indicação de medicamento para câncer de pulmão A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar uma nova indicação do medicamento Xalkori (crizotinibe). Lançado no País em...
SÃO PAULO, 3 de abril de 2018 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar uma nova indicação do medicamento Xalkori (crizotinibe). Lançado no País em 2016, para o tratamento do câncer de pulmão não pequenas células (CPNPC) avançado relacio
Read more →PFESUS incorpora medicamento da Pfizer para doença genética de origem portuguesa Foi publicada no dia 18 de janeiro de 2018, no Diário Oficial da União (DOU), a decisão do Ministério da Saúde de incorporar à lista de produtos...
SÃO PAULO, 18 de janeiro de 2018 /PRNewswire/ -- Foi publicada no dia 18 de janeiro de 2018, no Diário Oficial da União (DOU), a decisão do Ministério da Saúde de incorporar à lista de produtos distribuídos na rede pública de saúde o medicamento Vyndaqel (tafamidis), primeiro e ú
Read more →PFEEstudo reforça eficácia e segurança de medicamento da Pfizer para doença genética Um extenso estudo publicado pela revista científica Amyloid: The Journal of Protein Folding Disorders reforça o perfil de segurança e eficácia de...
SÃO PAULO, 19 de dezembro de 2017 /PRNewswire/ -- Um extenso estudo publicado pela revista científica Amyloid: The Journal of Protein Folding Disorders reforça o perfil de segurança e eficácia de Vyndaqel (tafamidis), da Pfizer, para o tratamento de pacientes com polineuropatia a
Read more →PFEPesquisa da Pfizer aponta que brasileiros querem viver muito, mas descuidam da saúde Os brasileiros desejam envelhecer com saúde e pretendem viver até os 85 anos, superando a expectativa de vida atual, que é de 75,5 anos, segundo o...
SÃO PAULO, 13 de dezembro de 2017 /PRNewswire/ -- Os brasileiros desejam envelhecer com saúde e pretendem viver até os 85 anos, superando a expectativa de vida atual, que é de 75,5 anos, segundo o Instituto Brasileiro de Geografia e Estatística. Mas a maioria não adota um estilo
Read more →PFETécnica inovadora da Pfizer revoluciona o tratamento da hemofilia Uma técnica capaz de inserir um gene saudável em células específicas pode revolucionar o tratamento de pacientes com doenças genéticas que,...
SÃO PAULO, 30 de novembro de 2017 /PRNewswire/ -- Uma técnica capaz de inserir um gene saudável em células específicas pode revolucionar o tratamento de pacientes com doenças genéticas que, atualmente, necessitam utilizar medicamentos por toda a vida, como é o caso da hemofilia.
Read more →PFECarlinhos Brown pausa show para alertar sobre doença genética em ação da Academia Brasileira de Neurologia Ao som do Timbal de Carlinhos Brown é difícil ficar parado. Mas esse será o desafio dos fãs soteropolitanos do cantor durante a festa Club du...
SÃO PAULO, 17 de novembro de 2017 /PRNewswire/ -- Ao som do Timbal de Carlinhos Brown é difícil ficar parado. Mas esse será o desafio dos fãs soteropolitanos do cantor durante a festa Club du Timball, marcada para o dia 19 de novembro, em Salvador (BA). Entre uma canção e outra,
Read more →PFEAssociação Pan-americana de Infectologia e Pfizer lançam campanha para alertar sobre resistência bacteriana Ao reduzir opções médicas para tratar infecções graves, a resistência bacteriana representa uma das principais ameaças à saúde global. A Organização...
SÃO PAULO, 14 de novembro de 2017 /PRNewswire/ -- Ao reduzir opções médicas para tratar infecções graves, a resistência bacteriana representa uma das principais ameaças à saúde global. A Organização Mundial de Saúde (OMS) estima que, a partir de 2050, mais de 10 milhões de pessoa
Read more →PFENeste Outubro Rosa, ação educativa da Pfizer e do Oncoguia mobiliza metrô e 800 táxis de São Paulo Se o paulistano gasta grande parte do seu dia no trânsito, que tal aproveitar esse período para aprender mais sobre o câncer de mama, o tipo de tumor ...
SÃO PAULO, 29 de setembro de 2017 /PRNewswire/ -- Se o paulistano gasta grande parte do seu dia no trânsito, que tal aproveitar esse período para aprender mais sobre o câncer de mama, o tipo de tumor mais comum entre as mulheres do Brasil? Com esse propósito, neste Outubro Rosa,
Read more →PFENational Sickle Cell Disease Poll of African Americans Dispels Long-Held Views Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new...
NEW YORK , Sept. 21, 2017 /PRNewswire-USNewswire/ -- Pfizer Inc. (NYSE: PFE ), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge perceptions around
Read more →PFEPfizer e CVV lançam campanha de prevenção do suicídio Se por um lado as discussões relacionadas ao suicídio vêm ganhando mais espaço na sociedade, ainda é preciso avançar no entendimento dos aspectos...
SÃO PAULO, 6 de setembro de 2017 /PRNewswire/ -- Se por um lado as discussões relacionadas ao suicídio vêm ganhando mais espaço na sociedade, ainda é preciso avançar no entendimento dos aspectos médicos ligados ao problema. Mais de 90% dos casos de suicídio estão associados a dis
Read more →PFEPesquisa da Pfizer revela que brasileiros com disfunção erétil planejam dia e hora para relações sexuais Entre os homens com disfunção erétil (DE), os brasileiros são os que mais planejam a vida sexual. É o que mostra a pesquisa global conduzida pela...
SÃO PAULO, 24 de julho de 2017 /PRNewswire/ -- Entre os homens com disfunção erétil (DE), os brasileiros são os que mais planejam a vida sexual. É o que mostra a pesquisa global conduzida pela Pfizer em sete países para investigar os hábitos sexuais dessa população. Mais de sete
Read more →PFEPesquisa realizada pela Pfizer aponta que brasileiros desconhecem câncer de rim A maioria dos brasileiros conhece pouco sobre o câncer de rim e considera que a divulgação sobre a doença no País é insuficiente. Além disso,...
SÃO PAULO, 14 de julho de 2017 /PRNewswire/ -- A maioria dos brasileiros conhece pouco sobre o câncer de rim e considera que a divulgação sobre a doença no País é insuficiente. Além disso, predominam percepções equivocadas em relação às causas, sintomas e tratamento do tumor. Ess
Read more →PFEVictor Mezei, Presidente da Pfizer Brasil, é eleito uma das personalidades mais influentes da saúde O presidente da Pfizer Brasil, Victor Mezei, foi eleito pela premiação 100 Mais Influentes da Saúde, da revista HealthCare Management, uma das...
SÃO PAULO, 19 de maio de 2017 /PRNewswire/ -- O presidente da Pfizer Brasil, Victor Mezei , foi eleito pela premiação 100 Mais Influentes da Saúde, da revista HealthCare Management, uma das personalidades mais influentes do setor no último ano, na categoria Entidades Setoriais. É
Read more →PFEPfizer traz para o mercado Centrum Vitamints, multivitamínico em formato de pastilhas mastigáveis Sentir-se bem e ter energia para realizar todas as atividades do dia a dia é desejo de todas as pessoas, no entanto, uma rotina agitada e cheia de...
SÃO PAULO, 12 de abril de 2017 /PRNewswire/ -- Sentir-se bem e ter energia para realizar todas as atividades do dia a dia é desejo de todas as pessoas, no entanto, uma rotina agitada e cheia de compromissos pode ser uma barreira para que tenham uma vida mais saudável. Pequenas m
Read more →PFEUnião Internacional de Controle do Câncer e Pfizer lançam nova fase de projeto mundial que apoia mulheres com metástase Até 30% das mulheres com câncer de mama passarão pelo processo de metástase, quando o tumor se espalha para outros órgãos, mesmo se a doença é...
SÃO PAULO, 30 de março de 2017 /PRNewswire/ -- Até 30% das mulheres com câncer de mama passarão pelo processo de metástase, quando o tumor se espalha para outros órgãos, mesmo se a doença é detectada precocemente, segundo a literatura médica. Mas, enquanto o financiamento global
Read more →PFESUS incorpora medicamento inovador da Pfizer para artrite reumatoide Foi publicada no último dia 2 de fevereiro, no Diário Oficial da União (DOU), a decisão do Ministério da Saúde de incorporar o medicamento Xeljanz...
SÃO PAULO, 7 de fevereiro de 2017 /PRNewswire/ -- Foi publicada no último dia 2 de fevereiro, no Diário Oficial da União (DOU), a decisão do Ministério da Saúde de incorporar o medicamento Xeljanz (citrato de tofacitinibe), indicado para o tratamento de artrite reumatoide ativa m
Read more →PFEPfizer é a empresa mais admirada do setor farmacêutico Conhecida por seu intenso trabalho na pesquisa e desenvolvimento de produtos inovadores, a Pfizer é hoje a empresa mais admirada do setor...
SÃO PAULO, 21 de dezembro de 2016 /PRNewswire/ -- Conhecida por seu intenso trabalho na pesquisa e desenvolvimento de produtos inovadores, a Pfizer é hoje a empresa mais admirada do setor farmacêutico no País. Essa é a conclusão do ranking As Empresas mais Admiradas no Brasil , r
Read more →PFEAção da Pfizer no Metrô mostra que paulistanos desconhecem informações básicas sobre câncer de mama Embora muito se fale sobre o câncer de mama, o desconhecimento sobre a doença ainda predomina entre os paulistanos. É o que mostram os resultados de...
SÃO PAULO, 30 de novembro de 2016 /PRNewswire/ -- Embora muito se fale sobre o câncer de mama, o desconhecimento sobre a doença ainda predomina entre os paulistanos. É o que mostram os resultados de um quiz sobre o tema aplicado a passageiros do Metrô em outubro. Mais de 80% dos
Read more →PFEGrande piquenique da Pfizer reunirá gerações para um dia de diversão no Parque Villa-Lobos Divertir-se com a família e os amigos, estimulando a convivência entre as diferentes gerações e a troca de experiências. Esse é o objetivo de um...
SÃO PAULO, 24 de novembro de 2016 /PRNewswire/ -- Divertir-se com a família e os amigos, estimulando a convivência entre as diferentes gerações e a troca de experiências. Esse é o objetivo de um grande piquenique que tomará conta do Parque Villa-Lobos no dia 27, domingo, a partir
Read more →PFEEstudo pioneiro da Pfizer desmistifica efeitos de anti-inflamatórios para o coração A revista científica New England Journal of Medicine acaba de publicar o primeiro grande estudo sobre a relação entre uso contínuo de...
SÃO PAULO, 17 de novembro de 2016 /PRNewswire/ -- A revista científica New England Journal of Medicine acaba de publicar o primeiro grande estudo sobre a relação entre uso contínuo de anti-inflamatórios não-esteroides e a saúde cardiovascular de pacientes crônicos. O trabalho, qu
Read more →PFEAnvisa aprova medicamento da Pfizer para doença genética irreversível A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou hoje o medicamento Vyndaqel (tafamidis), da Pfizer, primeiro e único tratamento...
SÃO PAULO, 8 de novembro de 2016 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou hoje o medicamento Vyndaqel (tafamidis), da Pfizer, primeiro e único tratamento específico para adultos com polineuropatia amilloidótica familiar (PAF), ou paramiloidose.
Read more →PFECálcio, vitamina D e atividade física: Pfizer alerta sobre trio fundamental para a saúde dos ossos Envelhecer com saúde e independência. A limitação física é o segundo maior receio dos brasileiros em relação ao envelhecimento, atrás apenas de...
SÃO PAULO, 20 de outubro de 2016 /PRNewswire/ -- Envelhecer com saúde e independência. A limitação física é o segundo maior receio dos brasileiros em relação ao envelhecimento, atrás apenas de problemas de saúde, de acordo com a pesquisa Como os Brasileiros Encaram o Envelhecimen
Read more →PFECom apoio de craques do futebol e da Pfizer, associação médica lança campanha de esclarecimento sobre doença genética Capaz de mobilizar torcidas e de inflamar paixões, o futebol tem canalizado esse prestígio para fazer a diferença na área da saúde. Se no passado...
SÃO PAULO, 19 de outubro de 2016 /PRNewswire/ -- Capaz de mobilizar torcidas e de inflamar paixões, o futebol tem canalizado esse prestígio para fazer a diferença na área da saúde. Se no passado ações envolvendo jogadores foram capazes de aumentar as doações de órgãos e de abaste
Read more →PFEPesquisa aponta Pfizer como líder em reputação do setor farmacêutico no Brasil A Pfizer apresenta uma imagem sólida e robusta no Brasil, sendo a companhia de maior reputação do setor farmacêutico. Essa é uma das conclusões da...
SÃO PAULO, 26 de setembro de 2016 /PRNewswire/ -- A Pfizer apresenta uma imagem sólida e robusta no Brasil, sendo a companhia de maior reputação do setor farmacêutico. Essa é uma das conclusões da avaliação Pharma RepTrak® 2016, um levantamento envolvendo 23.243 pessoas, de 15 pa
Read more →PFEPesquisa da Pfizer aponta ruídos na comunicação entre pacientes e médicos Estabelecer um bom diálogo e uma relação de confiança com o médico é fundamental para os pacientes crônicos, que necessitam de acompanhamento...
SÃO PAULO, 31 de agosto de 2016 /PRNewswire/ -- Estabelecer um bom diálogo e uma relação de confiança com o médico é fundamental para os pacientes crônicos, que necessitam de acompanhamento contínuo. Mas há fatores que podem provocar ruídos nessa comunicação, como mostra pesquisa
Read more →PFEPfizer lança no Brasil novas terapias-alvo contra câncer de pulmão e rim O ano de 2016 marca o fortalecimento do portfólio de oncologia da Pfizer no Brasil com a chegada de dois novos medicamentos ao País, um para câncer...
SÃO PAULO, 8 de julho de 2016 /PRNewswire/ -- O ano de 2016 marca o fortalecimento do portfólio de oncologia da Pfizer no Brasil com a chegada de dois novos medicamentos ao País, um para câncer de pulmão e outro para câncer renal, ambos classificados como terapia-alvo. Ao focar e
Read more →PFECom apoio da Pfizer, pesquisa traça novo perfil sexual do brasileiro As dificuldades sexuais são comuns entre os brasileiros, tanto para homens quanto para mulheres. Essa é uma das constatações da pesquisa Mosaico 2.0, ...
SÃO PAULO, 17 de junho de 2016 /PRNewswire/ -- As dificuldades sexuais são comuns entre os brasileiros, tanto para homens quanto para mulheres. Essa é uma das constatações da pesquisa Mosaico 2.0, um novo levantamento conduzido pela psiquiatra Carmita Abdo , coordenadora do Proje
Read more →PFEMedicamento da Pfizer é o primeiro anticorpo monoclonal biossimilar aprovado pelo FDA O medicamento Inflectra (infliximabe) acaba de se tornar o primeiro anticorpo monoclonal biossimilar aprovado pelo órgão regulatório norte-americano, ...
SÃO PAULO, 3 de maio de 2016 /PRNewswire/ -- O medicamento Inflectra (infliximabe) acaba de se tornar o primeiro anticorpo monoclonal biossimilar aprovado pelo órgão regulatório norte-americano, o Food and Drug Administration (FDA). Desenvolvido pela Celltrion, o produto é uma có
Read more →PFESociedade médica lança campanha contra pneumonia e pesquisa inédita da Pfizer mapeia impacto da doença no País No momento em que as atenções se voltam para os surtos de gripe por H1N1 no Brasil, outra enfermidade ganha destaque: a pneumonia, uma das principais ...
SÃO PAULO, 3 de maio de 2016 /PRNewswire/ -- No momento em que as atenções se voltam para os surtos de gripe por H1N1 no Brasil , outra enfermidade ganha destaque: a pneumonia, uma das principais causas de mortalidade no País. Isso porque a gripe facilita o deslocamento do nariz
Read more →PFEXalkori (crizotinibe), da Pfizer, é aprovado no Brasil para o tratamento de câncer de pulmão A Pfizer acaba de anunciar a aprovação do medicamento Xalkori (crizotinibe) pela Agência Nacional de Vigilância Sanitária (Anvisa). A terapia...
SÃO PAULO, 11 de fevereiro de 2016 /PRNewswire/ -- A Pfizer acaba de anunciar a aprovação do medicamento Xalkori (crizotinibe) pela Agência Nacional de Vigilância Sanitária (Anvisa). A terapia inovadora é indicada para o tratamento de câncer de pulmão de não pequenas células (CPN
Read more →PFEinstituições brasileiras participam dos estudos clínicos de fase 3 para novo medicamento da Pfizer contra o colesterol O Brasil acaba de ingressar na lista de países participantes de dois estudos clínicos internacionais de fase 3 envolvendo um medicamento inovador...
SÃO PAULO, 21 de janeiro de 2016 /PRNewswire/ -- O Brasil acaba de ingressar na lista de países participantes de dois estudos clínicos internacionais de fase 3 envolvendo um medicamento inovador desenvolvido pela Pfizer para o controle dos níveis do colesterol "ruim", o LDL-C, um
Read more →PFEAnvisa aprova novo medicamento da Pfizer para tratamento de câncer renal A Pfizer acaba de anunciar a aprovação do medicamento Inlyta (axitinibe) pela Agência Nacional de Vigilância Sanitária (Anvisa). A terapia, indicada...
SÃO PAULO, 14 de dezembro de 2015 /PRNewswire/ -- A Pfizer acaba de anunciar a aprovação do medicamento Inlyta (axitinibe) pela Agência Nacional de Vigilância Sanitária (Anvisa). A terapia, indicada para o tratamento de pacientes com carcinoma de células renais avançado (RCC, sig
Read more →PFEBrasileiros acreditam que metástase é rara em tumores de mama, diz pesquisa inédita da Pfizer Informações equivocadas e mitos relacionados ao câncer de mama metastático ainda predominam entre a população brasileira. É o que mostram os...
SÃO PAULO, 20 de outubro de 2015 /PRNewswire/ -- Informações equivocadas e mitos relacionados ao câncer de mama metastático ainda predominam entre a população brasileira. É o que mostram os resultados de uma pesquisa inédita, realizada pela Harris Poll em cinco países da América
Read more →PFEPesquisa inédita da Pfizer mostra que alívio rápido é o principal pensamento no momento da dor Em São Paulo, uma pesquisa inédita feita pelo IBOPE CONECTA em parceria com Advil, analgésico da Pfizer Consumer Healthcare, traçou o panorama A dor ...
SÃO PAULO, 15 de novembro de 2015 /PRNewswire/ -- Em São Paulo, uma pesquisa inédita feita pelo IBOPE CONECTA em parceria com Advil, analgésico da Pfizer Consumer Healthcare, traçou o panorama "A dor no cotidiano". O estudo realizado com 1.007 brasileiros com acesso à internet id
Read more →PFECrianças e jovens temem rugas e limitações na velhice, mostra pesquisa da Pfizer Vergonha de ir à praia, de ter rugas, de caminhar devagar. Esses são os principais temores de crianças e adolescentes quando se imaginam na terceira...
SÃO PAULO, 7 de outubro de 2015 /PRNewswire/ -- Vergonha de ir à praia, de ter rugas, de caminhar devagar. Esses são os principais temores de crianças e adolescentes quando se imaginam na terceira idade. É o que mostra a fase qualitativa da pesquisa "Como os brasileiros encaram o
Read more →PFEPfizer conclui aquisição de vacina contra meningite da GlaxoSmithKline A Pfizer anunciou hoje a conclusão da aquisição da vacina Nimenrix, da GlaxoSmithkline. Trata-se de uma vacina conjugada meningocócica quadrivalente, ...
SÃO PAULO, 1 de outubro de 2015 /PRNewswire/ -- A Pfizer anunciou hoje a conclusão da aquisição da vacina Nimenrix, da GlaxoSmithkline. Trata-se de uma vacina conjugada meningocócica quadrivalente, de dose única, criada para prevenir a meningite provocada pelos sorotipos A, C, W-
Read more →PFETrabalhar ajuda a enfrentar o tratamento contra o câncer, indica pesquisa inédita da Pfizer Trabalhar pode auxiliar na recuperação de pacientes oncológicos. Foi o que revelou uma pesquisa envolvendo mulheres com câncer de mama realizada pela ...
SÃO PAULO, 24 de setembro de 2015 /PRNewswire/ -- Trabalhar pode auxiliar na recuperação de pacientes oncológicos. Foi o que revelou uma pesquisa envolvendo mulheres com câncer de mama realizada pela organização sem fins lucrativos Cancer and Careers, em parceria com a Pfizer, no
Read more →PFECampanha da Pfizer propõe novo olhar sobre o envelhecimento Com o objetivo de redefinir o significado do envelhecimento, convocando brasileiros de todas as idades para o debate, a Pfizer acaba de lançar a...
SÃO PAULO, 31 de julho de 2015 /PRNewswire/ -- Com o objetivo de redefinir o significado do envelhecimento, convocando brasileiros de todas as idades para o debate, a Pfizer acaba de lançar a campanha "Envelhecer Sem Vergonha – Qualidade de vida não tem idade", uma iniciativa com
Read more →PFEDoença incapacitante afeta a vida profissional de adultos jovens no país, aponta pesquisa inédita da Pfizer Receber, aos 39 anos, o diagnóstico de uma doença crônica e progressiva, sem cura e com alto potencial incapacitante, provoca um profundo impacto na...
SÃO PAULO, 21 de julho de 2015 /PRNewswire/ -- Receber, aos 39 anos, o diagnóstico de uma doença crônica e progressiva, sem cura e com alto potencial incapacitante, provoca um profundo impacto na vida dos pacientes. Essa é a idade média em que os brasileiros com artrite reumatoid
Read more →PFEPfizer inaugura Centro de Excelência em Medicina de Precisão no Chile, com forte foco em análise genômica Em um evento realizado com a presença de autoridades, renomados cientistas, acadêmicos e líderes da Pfizer, foi inaugurado hoje o Centro de...
SANTIAGO, Chile , 8 de julho de 2015 /PRNewswire/ -- Em um evento realizado com a presença de autoridades, renomados cientistas, acadêmicos e líderes da Pfizer, foi inaugurado hoje o Centro de Excelência em Medicina de Precisão (CEMP) em Santiago , no Chile . Único em sua categor
Read more →PFEPesquisa da Pfizer revela que 94% das mulheres se incomodam com a pele do rosto A marca de nutricosmético Imedeen desenvolveu uma pesquisa inédita sobre o impacto do envelhecimento da pele do rosto na vida das mulheres. Realizada ...
SÃO PAULO, 25 de junho de 2015 /PRNewswire/ -- A marca de nutricosmético Imedeen desenvolveu uma pesquisa inédita sobre o impacto do envelhecimento da pele do rosto na vida das mulheres. Realizada pelo IBOPE Inteligência, a pesquisa O que a sua pele conta revela que 94% das mulhe
Read more →PFEPfizer Releases New Report Highlighting Underserved Latino Populations and Commits to Helping Those in Need A new edition of Pfizer's report on uninsured and underinsured Latinos – AVISO: An Update on the Hispanic Uninsured and Underinsured and How Pfizer...
LAS VEGAS , June 19, 2015 /PRNewswire/ -- A new edition of Pfizer's report on uninsured and underinsured Latinos – AVISO: An Update on the Hispanic Uninsured and Underinsured and How Pfizer Helps to Reduce Health Care Disparities – was presented today to attendees of the NALEO 32
Read more →PFEPfizer pone en circulación nuevo informe destacando las poblaciones de latinos menos favorecidos y se compromete a ayudar a los necesitados Una nueva edición del informe de Pfizer sobre latinos sin seguro médico y sin suficiente seguro médico – AVISO: una actualización sobre hispanos sin...
AVISO: durante la celebración del Congreso Anual de NALEO en Las Vegas se presentó a funcionarios electos una puesta al día sobre latinos con seguro médico y sin suficiente seguro médico y sobre cómo Pfizer ayuda a reducir las desigualdades en la asistencia médica para la salud
Read more →PFENovo medicamento da Pfizer para câncer de mama pode dobrar sobrevida livre de progressão da doença Um estudo de fase 3 (PALOMA-3) apresentado na 51ª Reunião Anual da Sociedade Americana de Oncologia Clínica (ASCO), encerrado no último dia 2,...
SÃO PAULO, 16 de junho de 2015 /PRNewswire/ -- Um estudo de fase 3 (PALOMA-3) apresentado na 51ª Reunião Anual da Sociedade Americana de Oncologia Clínica (ASCO), encerrado no último dia 2, indicou que o medicamento palbociclibe (Ibrance), da Pfizer, associado ao medicamento fulv
Read more →PFEPfizer traz ao Brasil tratamento inovador para artrite reumatoide Acaba de chegar ao Brasil uma nova classe de medicamentos para o tratamento da artrite reumatoide, doença progressiva e com alto potencial...
SÃO PAULO, 7 de maio de 2015 /PRNewswire/ -- Acaba de chegar ao Brasil uma nova classe de medicamentos para o tratamento da artrite reumatoide, doença progressiva e com alto potencial incapacitante que afeta cerca de 2 milhões de brasileiros. Xeljanz (citrato de tofacitinibe) tem
Read more →PFEAnvisa aprova indicação de vacina da Pfizer para crianças e adolescentes de 6 a 17 anos A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação da vacina Prevenar 13, que protege contra infecções causadas ...
SÃO PAULO, 2 de abril de 2015 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de ampliar no País a indicação da vacina Prevenar 13, que protege contra infecções causadas pela bactéria Streptococcus pneumoniae , como é o caso da pneumonia. Desenvolvido pe
Read more →PFEPfizer firma parceria com GRAACC e União Internacional de Controle do Câncer para fortalecer o combate à doença A Pfizer Brasil acaba de unir esforços com o GRAACC, instituição que possui um hospital de referência no tratamento oncológico infantojuvenil, para...
SÃO PAULO, 27 de março de 2015 /PRNewswire/ -- A Pfizer Brasil acaba de unir esforços com o GRAACC, instituição que possui um hospital de referência no tratamento oncológico infantojuvenil, para apoiar o combate aos tumores ocular e no sistema nervoso central. O hospital busca té
Read more →PFEEstudo com 85 mil pessoas comprova eficácia de vacina da Pfizer contra pneumonias pneumocócicas em idosos A revista The New England Journal of Medicine acaba de divulgar os resultados de um dos maiores estudos de eficácia de vacina já realizados em...
SÃO PAULO, 19 de março de 2015 /PRNewswire/ -- A revista The New England Journal of Medicine acaba de divulgar os resultados de um dos maiores estudos de eficácia de vacina já realizados em adultos, envolvendo cerca de 85 mil indivíduos de 65 anos ou mais. Duplo-cego, randomizado
Read more →PFEPesquisa inédita da Pfizer revela que 77% dos brasileiros com mais de 50 anos consideram a saúde a principal preocupação na vida Pesquisa inédita no Brasil revela que a maior preocupação dos brasileiros que têm 50 anos ou mais é com a saúde, porém a adoção de uma dieta...
SÃO PAULO, 6 de fevereiro de 2015 /PRNewswire/ -- Pesquisa inédita no Brasil revela que a maior preocupação dos brasileiros que têm 50 anos ou mais é com a saúde, porém a adoção de uma dieta balanceada e a prática de exercícios físicos ainda não é uma realidade para a maioria da
Read more →PFEFDA concede aprovação antecipada para novo medicamento da Pfizer contra câncer de mama O medicamento palbociclibe (Ibrance), usado em combinação com o fármaco letrozol, acaba de ser aprovado pelo órgão regulatório norte-americano, o...
SÃO PAULO, 5 de fevereiro de 2015 /PRNewswire/ -- O medicamento palbociclibe (Ibrance), usado em combinação com o fármaco letrozol, acaba de ser aprovado pelo órgão regulatório norte-americano, o Food and Drug Administration (FDA), como tratamento de primeira linha para mulheres
Read more →PFEApós transação com empresa suíça, Pfizer amplia seu portfólio de vacinas A Pfizer acaba de anunciar a aquisição do controle acionário da Redvax GMbH, subsidiária da Redbiotec AG, biofarmacêutica suíça com sede em...
SÃO PAULO, 12 de janeiro de 2015 /PRNewswire/ -- A Pfizer acaba de anunciar a aquisição do controle acionário da Redvax GMbH, subsidiária da Redbiotec AG, biofarmacêutica suíça com sede em Zurique-Schlieren. A transação permitirá o acesso aos testes pré-clínicos de uma vacina can
Read more →PFEPfizer recebe aprovação para lançar Xeljanz no Brasil e inaugura classe de medicamentos para artrite reumatoide A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar Xeljanz (citrato de tofacitinibe) para o tratamento de adultos com artrite...
SÃO PAULO, 8 de dezembro de 2014 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) acaba de aprovar Xeljanz (citrato de tofacitinibe) para o tratamento de adultos com artrite reumatoide (AR) de moderada a grave, que tiveram intolerância ou não responderam adequa
Read more →PFEEstratégias de aconselhamento empresarial ajudam colaboradores da Pfizer na carreira e no dia a dia Com o objetivo de estimular a troca de experiências e promover o diálogo entre seus colaboradores, a Pfizer adotou em sua rotina de trabalho...
SÃO PAULO, 28 de novembro de 2014 /PRNewswire/ -- Com o objetivo de estimular a troca de experiências e promover o diálogo entre seus colaboradores, a Pfizer adotou em sua rotina de trabalho diferentes formas de aconselhamento empresarial, que atingem vários níveis hierárquicos d
Read more →PFEEstudo mostra que antidepressivo da Pfizer tem baixo risco de provocar disfunção sexual em adultos com depressão Alterações na vida sexual são queixas frequentes entre pacientes tratados com antidepressivos. Mas um estudo americano recém-publicado pela revista...
NOVA YORK , 31 de outubro de 2014 /PRNewswire/ -- Alterações na vida sexual são queixas frequentes entre pacientes tratados com antidepressivos. Mas um estudo americano recém-publicado pela revista científica Journal of Clinical Psychiatry demonstrou que o risco de disfunção sexu
Read more →PFETratamento da Pfizer contra câncer de mama recebe revisão prioritária do FDA O medicamento palbociclib, usado em combinação com o fármaco letrozol, acaba de receber a revisão prioritária do órgão regulatório norte-americano, o ...
NOVA YORK , 23 de outubro de 2014 /PRNewswire/ -- O medicamento palbociclib, usado em combinação com o fármaco letrozol, acaba de receber a revisão prioritária do órgão regulatório norte-americano, o Food and Drug Administration (FDA), como tratamento de primeira linha para mulhe
Read more →PFEPesquisa inédita da Pfizer revela que 71% das mulheres no Brasil desconhecem a idade de início de uma das principais causas da osteoporose Uma pesquisa inédita no Brasil revela um dado importante para as mulheres. A Pesquisa A Hora Certa de Cuidar da Saúde dos Ossos, desenvolvida pela...
SÃO PAULO, 17 de outubro de 2014 /PRNewswire/ -- Uma pesquisa inédita no Brasil revela um dado importante para as mulheres. A Pesquisa A Hora Certa de Cuidar da Saúde dos Ossos , desenvolvida pela Pfizer Consumer Healthcare em parceria com a Associação Brasileira de Avaliação Óss
Read more →PFECientistas que desenvolveram antidepressivo da Pfizer são reconhecidos como Heróis da Química Os cientistas que desenvolveram a venlafaxina (Efexor®), medicamento da Pfizer usado para tratar o transtorno depressivo maior (TDM), foram...
SÃO PAULO, 2 de outubro de 2014 /PRNewswire/ -- Os cientistas que desenvolveram a venlafaxina (Efexor ® ), medicamento da Pfizer usado para tratar o transtorno depressivo maior (TDM), foram reconhecidos pela American Chemical Society (Sociedade Americana de Química) como "Heroes
Read more →PFENúmero de mulheres em cargos executivos na Pfizer dobra em seis anos Se o aumento das mulheres no mercado de trabalho brasileiro é notório nos últimos anos, garantir que elas cheguem a altos postos dentro das...
SÃO PAULO, 25 de agosto de 2014 /PRNewswire/ -- Se o aumento das mulheres no mercado de trabalho brasileiro é notório nos últimos anos, garantir que elas cheguem a altos postos dentro das organizações ainda é um desafio. Mas, na Pfizer, essa projeção feminina já é uma realidade.
Read more →PFEVacina para doenças pneumocócicas e pneumonia da Pfizer é recomendada nos Estados Unidos para adultos acima de 65 anos A vacina Prevenar 13, da Pfizer, foi recomendada pelo Comitê Consultivo de Práticas de Imunização (ACIP) do Centro de Controle e Prevenção de Doenças ...
NOVA YORK , 19 de agosto de 2014 /PRNewswire/ -- A vacina Prevenar 13, da Pfizer, foi recomendada pelo Comitê Consultivo de Práticas de Imunização (ACIP) do Centro de Controle e Prevenção de Doenças (CDC), dos Estados Unidos, para proteger adultos com 65 anos ou mais contra as do
Read more →PFEPesquisa da Pfizer mostra que Viagra é mais acessível do que se imagina Uma pesquisa realizada pelo IMS Consulting Group com 281 homens brasileiros mostrou que eles têm uma percepção equivocada sobre o preço do Viagra,...
SÃO PAULO, 22 de julho de 2014 /PRNewswire/ -- Uma pesquisa realizada pelo IMS Consulting Group com 281 homens brasileiros mostrou que eles têm uma percepção equivocada sobre o preço do Viagra, primeiro medicamento do mercado para tratar disfunção erétil, lançado pela Pfizer em 1
Read more →PFEParceria da BMS e Pfizer traz para o Brasil a segunda indicação de Eliquis® (apixabana) A Bristol-Myers Squibb e a Pfizer acabam de lançar no País a segunda indicação de Eliquis®(apixabana), voltada para a prevenção de acidente vascular...
SÃO PAULO, 18 de julho de 2014 / PRNewswire/ -- A Bristol-Myers Squibb e a Pfizer acabam de lançar no País a segunda indicação de Eliquis ® (apixabana), voltada para a prevenção de acidente vascular cerebral (AVC) em pacientes com fibrilação atrial não valvar (FANV). O medicamen
Read more →PFELos Hispanos y el Cáncer El cáncer es una palabra que nadie quiere escuchar cuando habla sobre sus amigos y familiares. Pero, con frecuencia alguien que conocemos es...
NUEVA YORK , 28 de mayo de 2013 /PRNewswire-HISPANIC PR WIRE/ -- El cáncer es una palabra que nadie quiere escuchar cuando habla sobre sus amigos y familiares. Pero, con frecuencia alguien que conocemos es diagnosticado con cáncer. De hecho, si usted es hispano, debe saber que se
Read more →PFEHot flashes and fashion: Know Your Options During the Holiday Season Fashion stylist Lisa Rogers gives her tips on staying cool while you're hot during menopause TORONTO, Dec. 5, 2011 /PRNewswire/ - Hot flashes are a...
Fashion stylist Lisa Rogers gives her tips on staying cool while you're hot during menopause TORONTO , Dec. 5, 2011 /PRNewswire/ - Hot flashes are a tough part of menopause for many women. However, women dressing for the holiday season can make smart fashion choices that look gr
Read more →PFEPrograma 'Promotores' de Pfizer ayuda a hispanos no asegurados y con seguro insuficiente De todos los países del mundo, tal vez ninguno sea tan étnicamente diverso como los Estados Unidos. La identidad de esta nación ha cambiado...
NUEVA YORK , 9 de diciembre /PRNewswire-HISPANIC PR WIRE/ -- De todos los países del mundo, tal vez ninguno sea tan étnicamente diverso como los Estados Unidos. La identidad de esta nación ha cambiado constantemente con el paso de los años, y el siglo XXI ha demostrado que no es
Read more →PFEDisparidad en la comunidad hispana: Acceso a una mejor salud Los medios de comunicación han estado detallando las aportaciones de la comunidad hispana en los Estados Unidos, particularmente luego que la Oficina ...
NUEVA YORK , 22 de septiembre /PRNewswire-HISPANIC PR WIRE/ -- Los medios de comunicación han estado detallando las aportaciones de la comunidad hispana en los Estados Unidos, particularmente luego que la Oficina del Censo anunciara la dramática alza poblacional de esa comunidad
Read more →Competitive Position
How PFE ranks across every disease it competes inCompetitive Position is a premium feature
See how PFE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial